| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 12, 2024 | LQDA Liquidia Corp | Manning Paul B54 | Director | Buy | 337,078 | $8.90 | $2,999,994.20 | +70.3% | +12.6% | +167.4% | |
| Sep 12, 2024 | SCYX Scynexis Inc | Angulo Gonzalez David | Chief Executive Officer | Buy | 20,000 | $1.37 | $27,400.00 | +4.1% | -11.9% | -16.4% | |
| Sep 12, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Frates James M83 | Chief Financial Officer | Buy | 40,000 | $2.53 | $101,368.00 | +20.7% | +75.5% | +367.9% | |
| Sep 11, 2024 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc.60 | 10% Owner | Buy | 107,500 | $4.70 | $504,875.00 | +2.0% | +151.4% | +266.8% | |
| Sep 9, 2024 | UTHR United Therapeutics Corp | Edgemond James | CFO And Treasurer | Sell | 7,802 | $345.41 | $2,694,888.82 | -36.4% | +5.2% | +15.8% | |
| Sep 9, 2024 | BSPK Bespoke Extracts, Inc. | Feinsod Michael | CEO | Buy | 2,000 | $0.12 | $230.00 | - | - | - | |
| Sep 6, 2024 | EOLS Evolus, Inc. | Beaver Sandra67 | Chief Financial Officer | Sell | 3,276 | $14.98 | $49,074.48 | -2.2% | -13.7% | -47.9% | |
| Sep 6, 2024 | BHC Bausch Health Companies Inc. | Carson Seana60 | EVP, General Counsel | Sell | 13,370 | $6.21 | $83,027.70 | -3.0% | +30.8% | +18.4% | |
| Sep 6, 2024 | COLL Collegium Pharmaceutical, Inc | Kuhlmann Shirley R.49 | EVP And General Counsel | Sell | 20,225 | $38.26 | $773,791.80 | -5.3% | -19.7% | +3.0% | |
| Sep 5, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Firestone Karen | Director | Buy | 50,000 | $2.13 | $106,590.00 | +1,000% | +139.1% | +363.6% | |
| Sep 5, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 3,000 | $46.47 | $139,417.20 | -3.8% | -2.5% | -35.2% | |
| Sep 5, 2024 | HIMS Hims & Hers Health, Inc. | Baird Melissa | Chief Operating Officer | Sell | 35,382 | $14.51 | $513,487.14 | -1.0% | +135.1% | +235.5% | |
| Sep 4, 2024 | PAHC Phibro Animal Health Corp | Corcoran E Thomas61 | Director | Buy | 5,000 | $20.02 | $100,100.00 | +25.0% | +18.4% | +98.8% | |
| Sep 4, 2024 | UTHR United Therapeutics Corp | Patusky Christopher50 | Director | Sell | 5,000 | $354.33 | $1,771,647.38 | -73.5% | +4.4% | +7.7% | |
| Sep 4, 2024 | VRNO Verano Holdings Corp. | Tarapchak Richard C | EVP, Finance | Sell | 10,536 | $3.37 | $35,503.16 | -9.5% | - | - | |
| Sep 3, 2024 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 11,609 | $14.60 | $169,478.51 | -1.6% | +112.8% | +206.6% | |
| Sep 3, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Milne George M Jr59 | Director | Buy | 100,000 | $2.20 | $219,800.00 | +13.2% | +156.9% | +355.6% | |
| Sep 3, 2024 | UTHR United Therapeutics Corp | Edgemond James | CFO And Treasurer | Sell | 7,785 | $362.37 | $2,821,050.45 | -40.8% | +5.0% | +11.1% | |
| Sep 3, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 24,084 | $966.69 | $23,281,840.23 | - | -16.4% | -22.9% | |
| Sep 3, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,345 | $14.65 | $34,354.25 | -1.4% | +112.8% | +206.6% | |
| Sep 3, 2024 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 333,332 | $14.53 | $4,844,923.95 | -28.7% | +112.8% | +206.6% | |
| Sep 3, 2024 | KNSA Kiniksa Pharmaceuticals International, Plc | Paolini John F.51 | Chief Medical Officer | Sell | 60,692 | $26.12 | $1,584,991.40 | -36.5% | -16.0% | +36.4% | |
| Sep 3, 2024 | LQDA Liquidia Corp | Schundler Russell58 | General Counsel | Sell | 710 | $9.50 | $6,744.79 | -0.1% | +23.4% | +221.1% | |
| Sep 3, 2024 | LQDA Liquidia Corp | Moomaw Scott | Chief Commercial Officer | Sell | 546 | $9.50 | $5,186.84 | -0.4% | +23.4% | +221.1% | |
| Sep 3, 2024 | LQDA Liquidia Corp | Kaseta Michael57 | CFO And COO | Sell | 1,079 | $9.50 | $10,250.18 | -0.3% | +23.4% | +221.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.